Skip to main content
Terug
Watch Compare

NeuroSense Therapeutics Ltd.

Datakwaliteit: 83%
Ook genoteerd als NRSNW Nasdaq
NRSN
Nasdaq Manufacturing Chemicals
€ 0,71
▼ € 0,01 (-1,39%)
Marktkapitalisatie: 23,74 M
Prijs
€ 0,71
Marktkapitalisatie
23,74 M
Dagbereik
€ 0,71 — € 0,73
52-Weeksbereik
€ 0,63 — € 2,60
Volume
99.126
Openen € 0,73
50D / 200D Gem.
€ 0,87
18,08% below
50D / 200D Gem.
€ 1,18
39,52% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -7,68 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,71
Interest CoverageN/A

Waardering

PE (TTM)
-2,13
Onder sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -2,1 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -11,13 M
ROE N/A ROA -631,21%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -7,68 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,71
Interest Coverage N/A Asset Turnover N/A
Working Capital -647.000 Tangible Book Value -519.000
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,13 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -32,34%
Market Cap 23,74 M Enterprise Value 23,08 M
Per Share
EPS (Diluted TTM) -0,44 Revenue / Share N/A
FCF / Share -0,23 OCF / Share -0,23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 69,02%
SBC-Adj. FCF -9,82 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2023 FY2024
Revenue — — —
Net Income -11,13 M -10,11 M -10,21 M
EPS (Diluted) -0,44 -0,74 -0,54
Gross Profit — — —
Operating Income -11,09 M -12,05 M -9,90 M
EBITDA — — —
R&D Expenses 6,23 M 7,27 M 5,70 M
SG&A Expenses — — —
D&A — — —
Interest Expense — — —
Income Tax — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2023 FY2024
Total Assets 1,03 M 3,19 M 4,58 M
Total Liabilities 2,59 M 4,94 M 1,99 M
Shareholders' Equity -1,56 M -1,76 M 2,58 M
Total Debt — — —
Cash & Equivalents 166.000,0 2,64 M 3,38 M
Current Assets 778.000,0 2,92 M 4,40 M
Current Liabilities 2,52 M 3,46 M 1,99 M